Biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage.
- Year invested 2017
- Investment Stage Growth
- Board Members
- Sectors
- Investment Status Current
- Website allakos.com
- Company Status IPO/Public (NASDAQ: ALLK)